Sharps Technology Pitch Deck Teardown: A Micro-Cap Public

Executive Summary and Introduction

Slide 1: Title Slide

The cover slide introduces Sharps Technology, Inc. (Nasdaq: STSS) with the tagline: "Collaboration. Innovation. Novel Technology. Making the World a Healthier Place." The visual features a 3D render of a syringe tray and individual syringes, emphasizing the physical product nature of the business. The slide is dated October 2023, positioning it shortly after a significant capital raise and contract signing.

Slide 4: Significant Developments

This slide serves as a historical timeline and traction summary. Key milestones include the company's founding in 2017 and the development of a product line that is FDA, WHO, and CE Mark approved. Crucially, it mentions that products are cleared for use by Pfizer and Moderna. The slide highlights the April 2022 IPO which raised $16M and the July 2022 acquisition of a manufacturing facility in Hungary at a "significant discount." The most vital piece of information is the September 2023 asset purchase agreement for the InjectEZ facility and a 10-year, $400 million purchase agreement from Nephron Pharmaceuticals. This slide establishes the company's shift from a development-stage entity to a commercial-scale manufacturer.

Product and Technology Deep Dive

Slide 7: Prefillable Syringes (PFS)

Slide 7 focuses on the technical specifications of the Prefillable Syringe systems. It outlines a "Proven Process" involving precision molds, advanced polymer materials, and ISO clean room assembly. The "Delivery Systems" section lists benefits such as glass-like transparency, high break resistance, and moisture barriers for drug stability. The slide explicitly states that PFS is a "strong preference in the medical industry over vial draw disposable syringes," positioning the company within a high-demand market segment. The visual includes a high-resolution render of a syringe with a safety closure.

Slide 10: Target Audience

This slide uses a global map to visualize the company's market opportunity and existing supplier ecosystem. It identifies "North American Suppliers" (BD), "Japanese Suppliers" (Taisei Kako, Terumo), and "European Suppliers" (Schott, Gerresheimer, Stevanato Group). More importantly, it maps out potential and current pharmaceutical partners, including Pfizer (Cold Chain Vaccines), Amgen (Multiple Biologics), AbbVie (BOTOX), and Nephron (Multiple 503B). This slide communicates the scale of the pharmaceutical companies Sharps intends to serve, suggesting a large Total Addressable Market (TAM).

Slide 13: Sharps Disposable Syringes Product Line

This is a transition slide featuring an architectural render of a manufacturing facility. The text emphasizes "Smart Safety Syringes designed for minimal waste and eco friendly initiatives." This aligns the company with ESG (Environmental, Social, and Governance) trends in healthcare, specifically addressing the waste generated by billions of disposable syringes annually.

Intellectual Property and Governance

Slide 16: Existing Patents

Slide 16 provides a comprehensive table of the company's intellectual property. It lists 25 patent entries across various jurisdictions including the United States, Australia, Canada, Europe, and Japan. The patents cover "Needle and syringe system with automatic safety shield," "Pre-filled safety needle," and "Ultra-low-waste disposable syringe." The status column shows a mix of "Active" and "Pending" applications. This slide is critical for a medical technology company, as it demonstrates the defensibility of their technology and the global scope of their IP protection.

Slide 19: Leadership Team

The leadership slide features four key executives. Robert Hayes (CEO) is credited with 25 years of healthcare experience at firms like Gerresheimer and Baxter. Soren Bo Christiansen, MD (Chairman) is highlighted as a former Merck President with $10B P&L responsibility. Andrew Crescenzo, CPA (CFO) and Steven Hertz, MD (CMO) round out the team with backgrounds in biotech finance and vascular surgery, respectively. The presence of a former Merck President on the board is a significant credibility marker for a micro-cap company.

Financials and Market Position

Slide 22: Key Statistics

The final slide in the provided set offers a snapshot of the company's public market data and financial health as of late 2023. Key figures include:

Market Cap: ~$9.5M · Share Price: $0.84 · Fully Diluted Shares: 41.5M · Insider Ownership: 16% · Revenue: Pre-revenue, with sales expected Q1 2024 · Cash: ~$4.1M (as of 12/31/22) plus a $5.6M raise on 9/29/23 · Debt: 0 · Employees: ~60

This slide is transparent about the company's pre-revenue status but points to the imminent Q1 2024 sales launch as the primary catalyst for investors.

What Sharps Technology Does Well

The deck excels at establishing credibility through association . By listing Pfizer, Moderna, and Merck (via their Chairman) and highlighting a $400 million contract with Nephron, the company mitigates the perceived risk of its small market cap. The inclusion of a detailed patent list (Slide 16) provides the technical due diligence necessary for medical device investors. Furthermore, the clear distinction between their two manufacturing hubs (Hungary and South Carolina) shows a concrete path to fulfilling the large Nephron contract.

What is Missing from the Deck

While the deck is strong on IP and partnerships, it lacks detailed unit economics . There is no mention of the manufacturing cost per unit versus the expected sale price, which is vital for understanding the path to profitability once revenue starts. Additionally, while the "Target Audience" slide (Slide 10) lists many big names, it does not clearly distinguish between "active customers," "signed pilots," and "prospective leads," other than the specific Nephron deal. Finally, there is no competitor comparison matrix ; while they list other suppliers like BD and Schott, they do not explicitly state how their "Smart Safety" technology outperforms these incumbents on cost or safety metrics.

Founder's Takeaway: What to Copy

Founders of pre-revenue hardware or med-tech companies should emulate the milestone-heavy traction slide (Slide 4). Instead of just listing goals, Sharps lists specific regulatory approvals (FDA, WHO, CE) and specific dollar amounts for acquisitions and raises. The Key Statistics slide (Slide 22) is also a model of transparency for public or late-stage private companies, providing a one-stop shop for valuation, share count, and cash position. Lastly, the IP table (Slide 16) is a professional way to present a complex patent portfolio, showing not just that they have patents, but where they are filed and their current status, which builds significant trust during the due diligence process.